Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$2.14 -0.9%	$2.06	$1.04 ▼ $3.73	$326.49M	1.15	2.20 million shs	5.48 million shs
RGNX REGENXBIO	$8.39 -4.1%	$8.97	$5.04 ▼ $15.36	$420.84M	1.09	926,600 shs	1.19 million shs
THTX Theratechnologies	$2.35 +0.4%	$2.62	$1.12 ▼ $3.13	$108.05M	0.6	821,373 shs	160,825 shs
VERV Verve Therapeutics	$11.30 +0.4%	$6.16	$2.86 ▼ $11.41	$1.01B	1.67	2.42 million shs	4.14 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	0.00%	+7.00%	+12.04%	-5.31%	-35.74%
RGNX REGENXBIO	0.00%	-0.47%	-6.47%	+7.15%	-27.11%
THTX Theratechnologies	0.00%	-7.11%	-9.62%	+56.67%	+51.61%
VERV Verve Therapeutics	0.00%	+2.17%	+145.65%	+116.48%	+125.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HRTX Heron Therapeutics	3.8881 of 5 stars	3.5	0.0	0.0	4.2	3.3	1.7	0.6
RGNX REGENXBIO	4.5434 of 5 stars	3.4	3.0	0.0	4.6	2.7	3.3	0.6
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	3.6186 of 5 stars	4.2	4.0	0.0	0.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	3.00	Buy	$5.00	133.64% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	276.94% Upside
THTX Theratechnologies	4.00	Strong Buy	N/A	N/A
VERV Verve Therapeutics	2.33	Hold	$14.57	28.95% Upside

Current Analyst Ratings Breakdown

Latest THTX, HRTX, RGNX, and VERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/15/2025	VERV Verve Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $24.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$144.29M	2.26	N/A	N/A	($0.22) per share	-9.73
RGNX REGENXBIO	$83.33M	5.05	N/A	N/A	$5.24 per share	1.60
THTX Theratechnologies	$85.87M	1.26	N/A	N/A	($0.55) per share	-4.27
VERV Verve Therapeutics	$32.33M	31.16	N/A	N/A	$5.83 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)
THTX Theratechnologies	-$8.31M	-$0.08	N/A	33.57	N/A	-4.18%	N/A	-0.37%	7/9/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest THTX, HRTX, RGNX, and VERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	N/A	2.40	1.76
RGNX REGENXBIO	N/A	2.93	2.93
THTX Theratechnologies	N/A	1.08	0.88
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
RGNX REGENXBIO	88.08%
THTX Theratechnologies	N/A
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	5.86%
RGNX REGENXBIO	12.79%
THTX Theratechnologies	N/A
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable
VERV Verve Therapeutics	110	89.14 million	71.40 million	Optionable

THTX, HRTX, RGNX, and VERV Headlines

Recent News About These Companies

BMO Capital Markets Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 28 at 8:04 AM | marketbeat.com

Verve Therapeutics' (VERV) Market Perform Rating Reiterated at BMO Capital Markets

June 28 at 2:35 AM | americanbankingnews.com

BMO Capital Markets Reiterates Market Perform Rating for Verve Therapeutics (NASDAQ:VERV)

June 27 at 1:39 PM | marketbeat.com

VERV Verve Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Eli Lilly's Strategic Acquisition of Verve Therapeutics

June 24, 2025 | pharmiweb.comP

GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

June 24, 2025 | marketbeat.com

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

June 23, 2025 | insidermonkey.com

Research Analysts Offer Predictions for VERV Q2 Earnings

June 21, 2025 | americanbankingnews.com

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

June 20, 2025 | fool.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

June 20, 2025 | globenewswire.com

Lifesci Capital Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 20, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Rating Lowered to "Neutral" at HC Wainwright

June 20, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Downgraded to "Hold" Rating by Jefferies Financial Group

June 20, 2025 | americanbankingnews.com

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19, 2025 | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19, 2025 | insidenova.comI

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19, 2025 | msn.com

Verve Therapeutics (NASDAQ:VERV) Lowered to Hold Rating by William Blair

June 19, 2025 | americanbankingnews.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18, 2025 | businesswire.com

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

June 18, 2025 | zacks.com

Verve Therapeutics (NASDAQ:VERV) Receives Neutral Rating from HC Wainwright

June 18, 2025 | marketbeat.com

Lifesci Capital Reaffirms "Market Perform" Rating for Verve Therapeutics (NASDAQ:VERV)

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

THTX, HRTX, RGNX, and VERV Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$2.14 -0.02 (-0.93%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.11 -0.03 (-1.40%)

As of 06/27/2025 05:43 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

REGENXBIO NASDAQ:RGNX

$8.39 -0.36 (-4.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.56 +0.17 (+2.03%)

As of 06/27/2025 07:57 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Theratechnologies NASDAQ:THTX

$2.35 +0.01 (+0.43%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.38 +0.02 (+1.06%)

As of 06/27/2025 04:04 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Verve Therapeutics NASDAQ:VERV

$11.30 +0.04 (+0.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.26 -0.04 (-0.39%)

As of 06/27/2025 07:57 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time